Hospital Clínico Pontificia Universidad Católica de Chile - Santiago, Región Metropolitana
Hospital Clínico Pontificia Universidad Católica de Chile - Santiago, Región Metropolitana
Portugal 61, Santiago
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Mariel Rosas
Verónica Contreras
Ruth Nuñes
Helda Gonzalez
Paula Burgos
Tarcisia Do Nascimento
César Sanchez
Maria Ines Salgado
Yorkaily Riquelme
Pablo A Gonzalez
Alexis M Kalergis
Open studies
Lung cancer
Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46) - KEYNOTE D46/EVOKE-03 - Merck Sharp & Dohme LLCSee more
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) - MK-2870-004 - Merck Sharp & Dohme LLCSee more
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - INTerpath-002 - Merck Sharp & Dohme LLCSee more
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] - MK-2870-023 - Merck Sharp & Dohme LLCSee more
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% - RELATIVITY1093 - Bristol-Myers SquibbSee more
Breast Cancer
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) - MK 2870-010 - Merck Sharp & Dohme LLCSee more
Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) - MK-6482-029 LITESPARK-029 - Merck Sharp & Dohme LLCSee more
Prostate cancer
Randomized Pilot Study of Radiosurgery for the Treatment of Non-metastatic Prostate Cancer - 210406002 - Pontificia Universidad Catolica de ChileSee more
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) - MK-5684-004 - Merck Sharp & Dohme LLCSee more
Advanced tumors
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) - Merck Sharp & Dohme LLCSee more
Cardiovascular Disease
Cervical cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) - MK-2870-020 - GOG FoundationSee more
Cholangitis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead SciencesSee more
Cirrhosis
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis - AFFIRM - Gilead SciencesSee more
Endometrial Cancer
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) - MK-2870-005 - GOG FoundationSee more
Lupus
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus - POETYK SLE-2 - Bristol-Myers SquibbSee more
Solid tumors
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) - Merck Sharp & Dohme LLCSee more
Syndromes with Skin Anomalies
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL - METRE-PL - Amryt PharmaSee more
Ulcerative colitis
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001) - MK-7240-001 - Merck Sharp & Dohme LLCSee more
Urothelial cancer
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 - KEYNOTE-D78 - Seagen Inc.See more
